<DOC>
	<DOCNO>NCT00253435</DOCNO>
	<brief_summary>RATIONALE : Radioactive drug , iodine I 131 metaiodobenzylguanidine , may carry radiation directly tumor cell harm normal cell . Drugs use chemotherapy , carboplatin , etoposide , melphalan , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . An autologous peripheral stem cell bone marrow transplant may able replace blood-forming cell destroy chemotherapy radiation therapy . Giving iodine I 131 metaiodobenzylguanidine combination chemotherapy autologous peripheral stem cell bone marrow transplant may allow chemotherapy give tumor cell kill . Giving radiation therapy autologous peripheral stem cell bone marrow transplant may kill remain tumor cell . PURPOSE : This phase II trial study well give iodine I 131 metaiodobenzylguanidine together combination chemotherapy radiation therapy work treat patient undergo autologous peripheral stem cell bone marrow transplant relapse refractory neuroblastoma .</brief_summary>
	<brief_title>N2001-02 : I-MIBG With Intensive Chemotherapy Autologous Stem Cell Rescue High-Risk Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient relapse refractory neuroblastoma treated iodine I 131 metaiodobenzylguanidine ( ^131I-MIBG ) combination chemotherapy comprise carboplatin , etoposide , melphalan follow autologous bone marrow peripheral blood stem cell transplantation radiotherapy . Secondary - Determine hematopoietic nonhematopoietic toxicity regimen patient . - Determine tumor self-absorbed radiation dose ( TSARD ) patient measurable soft tissue lesion treat regimen . - Correlate TSARD tumor response patient measurable residual soft tissue disease treat regimen . OUTLINE : This multicenter study . Patients stratify accord risk ( poor-risk group [ mixed response induction therapy progression induction therapy ] v good-risk group [ partial response 4 course induction therapy ] ) kidney function study entry ( glomerular filtration rate [ GFR ] ≥ 100 mL/min v GFR 60-99 mL/min ) - Stem cell harvest : Patients undergo peripheral blood stem cell harvest bone marrow harvest provide adequate number cell available . At least 2 week later , patient proceed iodine I 131 metaiodobenzylguanidine ( ^131I-MIBG ) combination chemotherapy . - 131I-MIBG combination chemotherapy : Patients receive ^131I-MIBG IV 2 hour day -21 , carboplatin IV continuously day -7 -4 , etoposide IV continuously day -7 -4 , melphalan IV 1 hour day -7 -5 . - Stem cell infusion filgrastim ( G-CSF ) : Three day completion chemotherapy , patient undergo transplantation either stem cell bone marrow day 0 . Patients also receive G-CSF subcutaneously IV 1 hour daily begin day 0 continue blood count return normal . - Radiotherapy : Once blood count return normal , patient undergo radiotherapy primary metastatic site receive previous irradiation 12 day begin day 42 . After completion study treatment , patient follow 2 year periodically thereafter . PROJECTED ACCRUAL : Approximately 50 patient ( 40 low-risk patient 8-10 high-risk patient ) accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis relapse refractory neuroblastoma Histologically confirm and/or demonstration tumor cell bone marrow elevate urinary catecholamine metabolite Highrisk neuroblastoma must meet one follow : Progressive disease prior completion induction therapy Mixed response response completion 4 course induction therapy Partial response 4 course induction therapy allow provide prior participation COGA3973 phase III COG trial Measurable disease , define least one metaiodobenzylguanidine ( MIBG ) avid target lesion determine diagnostic MIBG scan within 6 week study entry ( tumor sit receive local irradiation within 3 month study entry consider target lesion ) PATIENT CHARACTERISTICS : Performance status Lansky 60100 % OR Karnofsky 60100 % Life expectancy At least 2 month Hematopoietic Hemoglobin ≥ 10 g/dL Absolute neutrophil count ≥ 750/mm^3 Platelet count ≥ 50,000/mm^3 ( marrow involvement morphologic exam/no transfusion allow ) ( &gt; 20,000/mm^3 metastatic tumor involvement marrow morphologic exam/transfusion allow ) Hepatic Bilirubin &lt; 1.3 mg/dL SGOT SGPT &lt; 5 time normal Hepatitis B surface antigen negative Hepatitis C negative Renal Glomerular filtration rate creatinine clearance ≥ 60 ml/min Creatinine ≤ 1.5 time normal age follow : 0.8 mg/dL ( patient ≤ 5 year age ) 1.0 mg/dL ( patient 6 10 year age ) 1.2 mg/dL ( patient 11 15 year age ) 1.5 mg/dL ( patient &gt; 15 year age ) Cardiovascular Ejection fraction ≥ 55 % echocardiogram radionuclide MUGA OR Fractional shorten ≥ 27 % echocardiogram Pulmonary Normal lung function define dyspnea rest oxygen requirement OR measure oxygen saturation &gt; 93 % room air Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No disease major organ system would preclude study compliance No concurrent hemodialysis No active infection require IV antiviral , antibiotic , antifungal ( patient antifungal therapy eligible provided culture biopsynegative suspect residual radiographic lesion ) Patient weight within limit receive ≤ maximum total allowable dose ^131IMIBG PRIOR CONCURRENT THERAPY : Biologic therapy No prior myeloablative transplantation Prior submyeloablative transplantation allow discretion principal investigator More 3 week since prior biologic therapy Chemotherapy More 3 week since prior myelosuppressive chemotherapy ( 6 week mitomycin C nitrosoureas ) No prior melphalan therapy total dose &gt; 100 mg/m^2 Radiotherapy See Disease Characteristics At least 6 week since prior radiotherapy ( 6 month craniospinal whole lung radiotherapy ) No prior total body irradiation No prior iodine I 131 MIBG ( ^131IMIBG ) No prior total abdominal whole liver radiotherapy No prior local radiotherapy , include follow : 1200 cGy 33 % kidney ( patient must least one kidney exceed dose/volume radiation list ) 1800 cGy 30 % liver and/or 900 cGy 50 % liver Other Recovered prior therapy No medication potential interference ^131IMIBG uptake 1 week 2 week completion ^131IMIBG</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
</DOC>